MX2016014355A - Metodo para seleccionar anticuerpos con interaccion del receptor de fc neonatal (fcrn) modificado. - Google Patents

Metodo para seleccionar anticuerpos con interaccion del receptor de fc neonatal (fcrn) modificado.

Info

Publication number
MX2016014355A
MX2016014355A MX2016014355A MX2016014355A MX2016014355A MX 2016014355 A MX2016014355 A MX 2016014355A MX 2016014355 A MX2016014355 A MX 2016014355A MX 2016014355 A MX2016014355 A MX 2016014355A MX 2016014355 A MX2016014355 A MX 2016014355A
Authority
MX
Mexico
Prior art keywords
full length
numbering
positions
antibodies
heavy chain
Prior art date
Application number
MX2016014355A
Other languages
English (en)
Inventor
Kettenberger Hubert
Schlothauer Tilman
Foged Jensen Pernille
Koenig Maximiliane
Rand Kasper
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MX2016014355A publication Critical patent/MX2016014355A/es

Links

Classifications

    • F—MECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
    • F25—REFRIGERATION OR COOLING; COMBINED HEATING AND REFRIGERATION SYSTEMS; HEAT PUMP SYSTEMS; MANUFACTURE OR STORAGE OF ICE; LIQUEFACTION SOLIDIFICATION OF GASES
    • F25D—REFRIGERATORS; COLD ROOMS; ICE-BOXES; COOLING OR FREEZING APPARATUS NOT OTHERWISE PROVIDED FOR
    • F25D31/00—Other cooling or freezing apparatus
    • F25D31/002—Liquid coolers, e.g. beverage cooler
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/522—CH1 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • F—MECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
    • F25—REFRIGERATION OR COOLING; COMBINED HEATING AND REFRIGERATION SYSTEMS; HEAT PUMP SYSTEMS; MANUFACTURE OR STORAGE OF ICE; LIQUEFACTION SOLIDIFICATION OF GASES
    • F25D—REFRIGERATORS; COLD ROOMS; ICE-BOXES; COOLING OR FREEZING APPARATUS NOT OTHERWISE PROVIDED FOR
    • F25D2600/00—Control issues
    • F25D2600/04—Controlling heat transfer
    • F—MECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
    • F25—REFRIGERATION OR COOLING; COMBINED HEATING AND REFRIGERATION SYSTEMS; HEAT PUMP SYSTEMS; MANUFACTURE OR STORAGE OF ICE; LIQUEFACTION SOLIDIFICATION OF GASES
    • F25D—REFRIGERATORS; COLD ROOMS; ICE-BOXES; COOLING OR FREEZING APPARATUS NOT OTHERWISE PROVIDED FOR
    • F25D2700/00—Means for sensing or measuring; Sensors therefor
    • F25D2700/16—Sensors measuring the temperature of products

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Combustion & Propulsion (AREA)
  • Physics & Mathematics (AREA)
  • Mechanical Engineering (AREA)
  • Thermal Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Devices That Are Associated With Refrigeration Equipment (AREA)

Abstract

La presente invención se refiere a un método para seleccionar un anticuerpo de longitud completa que comprende las etapas de a) generar de un anticuerpo de longitud completa precursor una pluralidad de anticuerpos de longitud completa aleatorizando uno o más residuos de aminoácido seleccionados a partir de los residuos de aminoácido en las posiciones 1-23 en el dominio variable de cadena pesada (numeración de conformidad con Kabat), en las posiciones 55-83 en el dominio variable de cadena ligera (numeración de conformidad con Kabat), en las posiciones 145-174 en el primer dominio constante de cadena pesada (numeración de conformidad con el índice EU) y en las posiciones 180- 97 en el primer dominio constante de cadena pesada (numeración de conformidad con el índice EU), b) determinar la intensidad de unión de cada uno de los anticuerpos de longitud completa a partir de la pluralidad de anticuerpos al receptor Fc neonatal humano (FcRn), y c) seleccionar un anticuerpo de longitud completa a partir de la pluralidad de anticuerpos de longitud completa que tiene una diferente intensidad de unión al FcRn que el anticuerpo de longitud completa precursor.
MX2016014355A 2014-06-12 2015-06-10 Metodo para seleccionar anticuerpos con interaccion del receptor de fc neonatal (fcrn) modificado. MX2016014355A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP14172180 2014-06-12
PCT/EP2015/062899 WO2015189249A1 (en) 2014-06-12 2015-06-10 Method for selecting antibodies with modified fcrn interaction

Publications (1)

Publication Number Publication Date
MX2016014355A true MX2016014355A (es) 2017-01-27

Family

ID=50933041

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016014355A MX2016014355A (es) 2014-06-12 2015-06-10 Metodo para seleccionar anticuerpos con interaccion del receptor de fc neonatal (fcrn) modificado.

Country Status (10)

Country Link
US (2) US20170211876A1 (es)
EP (1) EP3155013B1 (es)
JP (2) JP6675329B2 (es)
KR (1) KR20170015920A (es)
CN (1) CN106459191B (es)
BR (1) BR112016025393A2 (es)
CA (1) CA2946430A1 (es)
MX (1) MX2016014355A (es)
RU (1) RU2714153C2 (es)
WO (1) WO2015189249A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20250036943A (ko) 2016-08-02 2025-03-14 비스테라, 인크. 조작된 폴리펩티드 및 그의 용도
WO2019077092A1 (en) * 2017-10-20 2019-04-25 F. Hoffmann-La Roche Ag METHOD FOR GENERATING MULTISPECIFIC ANTIBODIES FROM MONOSPECIFIC ANTIBODIES
KR102831164B1 (ko) 2017-10-30 2025-07-07 에프. 호프만-라 로슈 아게 단일특이적 항체로부터 다중특이적 항체의 생체내 생성 방법
EP3870331B1 (en) * 2018-10-25 2025-07-23 F. Hoffmann-La Roche AG Modification of antibody fcrn binding
TW202120539A (zh) * 2019-07-25 2021-06-01 美商健臻公司 以FcRn拮抗劑治療抗體媒介之病症的方法
EP4045536A4 (en) * 2019-10-16 2023-11-01 Lg Chem, Ltd. Neonatal fc receptor binding affimers
IL295545A (en) * 2020-02-14 2022-10-01 Janssen Biotech Inc Safe and effective method of treating ulcerative colitis with anti-il-12/il23 antibody
KR20240003224A (ko) * 2022-06-30 2024-01-08 코웨이 주식회사 냉수 탱크 조립체

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1355919E (pt) * 2000-12-12 2011-03-02 Medimmune Llc Moléculas com semivida longa, composições que as contêm e suas utilizações
US7217797B2 (en) * 2002-10-15 2007-05-15 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
US7361740B2 (en) * 2002-10-15 2008-04-22 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
RU2337107C2 (ru) * 2003-05-02 2008-10-27 Ксенкор, Инк. ОПТИМИЗИРОВАННЫЕ Fc-ВАРИАНТЫ, ИМЕЮЩИЕ ИЗМЕНЕННОЕ СВЯЗЫВАНИЕ С FcγR, И СПОСОБЫ ИХ ПОЛУЧЕНИЯ
RU2412200C2 (ru) * 2004-11-12 2011-02-20 Ксенкор, Инк. Fc-ВАРИАНТЫ С ИЗМЕНЕННЫМ СВЯЗЫВАНИЕМ С FcRn
EP2666787B1 (en) * 2007-05-31 2022-02-09 Genmab A/S STABLE IgG4 ANTIBODIES
US20090130105A1 (en) * 2007-08-28 2009-05-21 Biogen Idec Ma Inc. Compositions that bind multiple epitopes of igf-1r
WO2010017595A1 (en) * 2008-08-14 2010-02-18 Arana Therapeutics Limited Variant domain antibodies
EP2233500A1 (en) * 2009-03-20 2010-09-29 LFB Biotechnologies Optimized Fc variants
TWI667257B (zh) * 2010-03-30 2019-08-01 中外製藥股份有限公司 促進抗原消失之具有經修飾的ＦｃＲｎ親和力之抗體
EP3029066B1 (en) * 2010-07-29 2019-02-20 Xencor, Inc. Antibodies with modified isoelectric points
CA2851534C (en) * 2011-10-10 2023-02-14 Xencor, Inc. A method for purifying antibodies
MX2014014894A (es) * 2012-06-04 2015-02-20 Irm Llc Metodos de marcado especifico del sitio y moleculas producidas mediante los mismos.
PL3250610T3 (pl) * 2015-01-30 2024-01-29 Momenta Pharmaceuticals, Inc. Przeciwciała anty-FcRn i sposoby ich stosowania
EP4295154A1 (en) * 2021-02-18 2023-12-27 F. Hoffmann-La Roche AG Method for resolving complex, multistep antibody interactions

Also Published As

Publication number Publication date
JP2020114217A (ja) 2020-07-30
CN106459191A (zh) 2017-02-22
KR20170015920A (ko) 2017-02-10
CA2946430A1 (en) 2015-12-17
US20170211876A1 (en) 2017-07-27
RU2016150952A (ru) 2018-07-12
RU2016150952A3 (es) 2019-02-07
JP2017525335A (ja) 2017-09-07
EP3155013B1 (en) 2019-03-27
JP7050838B2 (ja) 2022-04-08
EP3155013A1 (en) 2017-04-19
JP6675329B2 (ja) 2020-04-01
RU2714153C2 (ru) 2020-02-12
US20210041163A1 (en) 2021-02-11
BR112016025393A2 (pt) 2017-12-12
WO2015189249A1 (en) 2015-12-17
CN106459191B (zh) 2021-12-10

Similar Documents

Publication Publication Date Title
MX2016014355A (es) Metodo para seleccionar anticuerpos con interaccion del receptor de fc neonatal (fcrn) modificado.
CY1124993T1 (el) Ετεροδιμερικα αντισωματα που δεσμευουν cd3 και cd20
MX2021003549A (es) Anticuerpos dobles especificos.
CL2018000461A1 (es) Anticuerpos biespecíficos con tetravalencia para un receptor de fnt coestimulador.
CO2017006740A2 (es) Anticuerpos anti–cd79b
DOP2018000259A (es) Proteínas de unión biespecíficas que se unen a una proteína inmunomoduladora y a un antígeno tumoral
MX2016012880A (es) Cadena j modificada.
CO2018011364A2 (es) Anticuerpos anti-il-33, composiciones, métodos y usos de los mismos
MX2017012802A (es) Anticuerpos antisortilina y métodos para su uso.
MX2017000985A (es) Anticuerpos anti-pd-1.
EA201792467A1 (ru) Гетеродимерные антитела, которые связывают cd3 и опухолевые антигены
MX373245B (es) Anticuerpos cd3 humanizados o quiméricos.
NI201700037A (es) Diacuerpos monovalentes biespecíficos que son capaces de unir cd19 y cd3, y usos de los mismos
CL2016003346A1 (es) Anticuerpos anti-tau humanizados
EA201791029A1 (ru) Антитела против интерлейкина-33 и их применение
CO2018013298A2 (es) Anticuerpos anti-gitr y sus usos.
PE20240111A1 (es) Moleculas de union a pd-1 y metodos de uso de las mismas
EA201791164A1 (ru) Гетеродимерные антитела, связывающие cd3 и cd38
CU24533B1 (es) Anticuerpos o fragmentos de los mismos que se unen a linfopoyetina estromal tímica (tslp) y composiciones farmacéuticas de los mismos
UY36942A (es) Proteínas de unión a antígeno que activan el receptor de leptina
MX353278B (es) Raton con cadena ligera comun.
MX376026B (es) Inmunoreceptores especificos de claudina-6 y epitopos de celulas t.
MX390385B (es) Anticuerpos anti-pd-l1.
BR112016014731A2 (pt) Anticorpos anti-baff
CY1125400T1 (el) Νεα αντι-ανθρωπινα αντισωματα gpvi και χρησεις αυτων

Legal Events

Date Code Title Description
FG Grant or registration